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Abstract: Background The current standard of care (SOC) for pediatric venous thromboembolism (VTE)
comprises unfractionated heparin (UFH), or low-molecular-weight heparin (LMWH) followed by LMWH
or vitamin K antagonists, all of which have limitations. Dabigatran etexilate (DE) has demonstrated
efficacy and safety for adult VTE and has the potential to overcome some of the limitations of the
current SOC. Pediatric trials are needed to establish dosing in children and to confirm that results
obtained in adults are applicable in the pediatric setting. Objectives To describe the design and rationale
of a planned phase IIb/III trial that will evaluate a proposed dosing algorithm for DE and assess the
safety and efficacy of DE versus SOC for pediatric VTE treatment. Patients/Methods An open-label,
randomized, parallel-group noninferiority study will be conducted in approximately 180 patients aged 0
to <18 years with VTE, who have received initial UFH or LMWH treatment and who are expected to
require ￿3 months of anticoagulation therapy. Patients will receive DE or SOC for 3 months. DE will
be administered twice daily as capsules, pellets, or an oral liquid formulation according to patient age.
Initial doses will be calculated using a proposed dosing algorithm. Results There will be two coprimary
endpoints: a composite efficacy endpoint comprising the proportion of patients with complete thrombus
resolution, freedom from recurrent VTE and VTE-related mortality, and a safety endpoint: freedom from
major bleeding events. Conclusion Findings will provide valuable information regarding the efficacy and
safety of DE for the treatment of pediatric VTE. ClinicalTrials.gov registration number: NCT01895777.
DOI: https://doi.org/10.1002/rth2.12086
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VTE	 in	 the	pediatric	population	 is	 approximately	0.07-	0.14	events	






The	 current	 standard	 of	 care	 (SOC)	 in	 pediatric	 VTE	 is	 initial	
treatment	 with	 unfractionated	 heparin	 (UFH)	 or	 low-	molecular-	
weight	heparin	(LMWH),	then	followed	by	LMWH	or	vitamin	K	an-
tagonists	 (VKA).6–8	 However,	 all	 of	 these	 agents	 have	 limitations;	





Treatment	 recommendations	 for	 children	 are	 similar	 to	 those	
for	adults	and	are	based	on	extrapolation	of	data	from	adult	clinical	
trials.8	 Nevertheless,	 there	 are	 important	 differences	 to	 consider	
with	 regard	 to	 VTE	 epidemiology	 and	management	 in	 adults	 and	
children	 (especially	 in	 very	 young	 children).	 First,	 unlike	 in	 adults,	
VTEs	 in	 children	 usually	 occur	 secondarily	 to	 another	 identifiable	
risk	 factor,	most	 commonly	 the	presence	of	 a	 central	 venous	 line,	
particularly	 in	neonates	and	 infants.	Other	risk	factors	 include	un-
derlying	conditions	such	as	cancer	or	congenital	heart	disease.2,8,9 















Patients/Methods:	 An	 open-	label,	 randomized,	 parallel-	group	 noninferiority	 study	
will	be	conducted	in	approximately	180	patients	aged	0	to	<18	years	with	VTE,	who	
have	 received	 initial	 UFH	 or	 LMWH	 treatment	 and	 who	 are	 expected	 to	 require	
≥3	months	of	anticoagulation	therapy.	Patients	will	receive	DE	or	SOC	for	3	months.	
DE	will	be	administered	twice	daily	as	capsules,	pellets,	or	an	oral	liquid	formulation	






Conclusion:	 Findings	will	 provide	 valuable	 information	 regarding	 the	 efficacy	 and	
safety	of	DE	for	the	treatment	of	pediatric	VTE.	ClinicalTrials.gov	registration	num-
ber:	NCT01895777.








     |  349ALBISETTI ET AL.
than	adults,	thus	offering	a	potential	benefit	over	UFH/LMWH,	which	
act by directly binding antithrombin.6	To	date,	 findings	 from	studies	
conducted	in	children	and	adolescents	are	comparable	to	those	seen	
in	 adults	 in	 terms	 of	 safety	 and	 pharmacokinetic	 (PK)/pharmacody-
namic	(PD)	relationships	(Table	1).15–17	Moreover,	because	dabigatran	





















The	 target	 population	 will	 comprise	male	 and	 female	 patients	
aged	0-	17	years	with	an	objectively	confirmed	diagnosis	of	VTE	(eg,	
deep	vein	thrombosis,	pulmonary	embolism,	and/or	cerebral	venous	
sinus	 thrombosis).	 Individuals	who	 have	 received	 initial	 parenteral	





Patients	will	 be	 stratified	 into	 three	age	groups:	 stratum	1	 (12	






international	 regulations.	 Written	 informed	 consent	 must	 be	 ob-
tained	from	patients	or	their	legal	representatives	according	to	the	
International	Conference	on	Harmonisation	Good	Clinical	Practice21 
and	 the	 regulatory	 and	 legal	 requirements	 of	 each	 participating	
country.	The	 trial	will	be	conducted	according	 to	 the	principles	of	
Good	Clinical	Practice.	Trial-	related	monitoring,	audits,	institutional	
TABLE  1 Clinical	studies	of	DE	in	pediatric	subjects





















































































for	 the	 dosing	 of	DE,	 and	 therefore	 the	 dosing	 in	 children	 differs	
from	adult	 dosing.	Whereas	 changes	 in	 renal	 function	 are	physio-
logical	across	 the	years	of	childhood,	maturation	of	 renal	 function	
is	completed	after	adolescence	allowing	for	simplified	fixed	dosing	
in	 healthy	 adults.	 Dosing	 based	 on	 Hayton’s	 formula19	 accounts	
for	 the	maturation	of	 renal	 function	across	 childhood,	 resulting	 in	
a	more	 individualized	 dosing	 algorithm	 in	 children.	 As	 renal	 func-
tion	 in	children	and	adolescents	 is	 relatively	higher	 than	 in	adults,	
dose	 estimations	were	 based	 on	 a	 young	 adult	 patient	 (reference	
patient:	20	years	old;	70	kg)	whose	renal	function	more	closely	re-
sembled	 that	of	 the	 target	pediatric	population.	Hayton	predicted	
a	glomerular	filtration	rate	of	136	mL/min	for	a	20-	year-	old	patient	
of	70	kg	body	weight.19	To	achieve	the	median	trough	exposure	as	
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The	chosen	dosing	nomogram	based	on	Hayton’s	formula19	has	





















patients	with	an	unresolved	clinical	 risk	 factor	at	 the	end	of	 the	3-	
month	 treatment	 period	may	 continue	 into	 study	NCT02197416,	 a	
phase	III,	single-	arm	study	of	DE	for	secondary	VTE	prevention	in	pa-
tients	aged	0	to	<18	years,	who	will	be	evaluated	for	up	to	12	months.
The	 coprimary	endpoints	 are	 as	 follows:	 (i)	 composite	 efficacy	
endpoint:	 the	proportion	of	patients	with	complete	 thrombus	 res-
olution,	 freedom	 from	 recurrent	 VTE	 (including	 symptomatic	 and	





decrease	 in	hemoglobin	of	at	 least	20	g/L	 in	24	h,	bleeding	 that	 is	




































































ALT,	 alanine	 aminotransferase;	 AP,	 alkaline	 phosphatase;	 AST,	 alanine	
aminotransferase;	DE,	dabigatran	etexilate;	DVT,	deep	vein	thrombosis;	
eGFR,	 estimated	 glomerular	 filtration	 rate;	 LMWH,	 low-	molecular-	
weight	heparin;	PE,	pulmonary	embolism;	UFH,	unfractionated	heparin;	
ULN,	upper	limit	of	normal;	VTE,	venous	thromboembolism.
















For	 the	 efficacy	 coprimary	 endpoint,	 an	 intent-	to-	treat	
analysis	 will	 be	 performed	 on	 the	 randomized	 set;	 data	 will	
be	 stratified	 by	 age	 group	 using	 a	 Mantel-	Haenszel–type	
weighted	 average	 of	 differences.	 The	 safety	 coprimary	 end-






















limitations	of	 the	current	SOC,	which	 include	 the	 requirement	 for	
coagulation	monitoring	 (for	VKA),	variable	PK,	 the	risk	of	heparin-	
induced	thrombocytopenia	(for	UFH),	and	parenteral	administration	
and	dependency	on	antithrombin	 levels	 (for	UFH	and	LMWH).5,6,8 
























































namic;	 PK,	 pharmacokinetic;	 SOC,	 standard	 of	 care;	 VTE,	 venous	
thromboembolism.
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leading	experts	in	a	given	field	and	benefitting	from	their	first-	hand	










There	 are	 several	 issues	 in	designing	 and	 conducting	 trials	 of	
antithrombotic	therapy	 in	children.	First,	dosing	must	be	adapted	
to	 the	 pediatric	 population,	 taking	 into	 account	 developmental	
changes	in	the	hemostatic	system	and	an	individual	child’s	weight	
(or	 weight	 and	 age).41	 As	 previously	 discussed,	 the	 dosing	 strat-
egy	 in	the	current	study	has	been	carefully	considered	and	 is	ex-
pected	 to	 result	 in	 safe	 and	 effective	 DE	 doses.	 Another	 major	
challenge	 in	 conducting	 large	 anticoagulant	 trials	 in	 children	 is	
the	 low	 frequency	of	 pediatric	VTE.41	 For	 example,	 slow	 recruit-
ment	was	 the	 reason	 for	early	 termination	of	 two	previous	pedi-
atric	 antithrombotic	 trials,	 PROphylaxis	 of	 ThromboEmbolism	 in	
Kids	Trial	(PROTEKT)	and	REVIparin	in	Venous	ThromboEmbolism	
(REVIVE).42	In	both	studies,	the	final	sample	size	was	not	sufficient	
to	 achieve	 the	 anticipated	 power.42	 The	 target	 enrollment	 count	
of	180	patients	in	the	current	study	is	considered	to	be	achievable	












population	 and	 due	 to	 the	 difficulties	 associated	 with	 comparing	














effects	on	prevention	of	 long-	term	complications	of	DVT,	 such	 as	
post-	thrombotic	syndrome,	which	usually	takes	at	least	1	year	to	de-
velop	following	the	DVT	event.
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